EYENOVIA INC. - COMMO

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

25 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Eyenovia Provides Update on Restructuring Efforts

22 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Provides Update on Phase 3 CHAPERONE Study

15 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

01 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

27 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

26 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Closing of Public Offering

23 Aug 2024 11:42:23 By Nasdaq GlobeNewswire

Eyenovia Announces Pricing of $5.14 Million Public Offering

21 Aug 2024 09:29:09 By Nasdaq GlobeNewswire

Eyenovia, Inc. Announces Proposed Public Offering

20 Aug 2024 17:09:50 By Nasdaq GlobeNewswire

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

07 Aug 2024 17:11:42 By Nasdaq GlobeNewswire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire